QKI
QKI (KH domain-containing RNA-binding protein QKI) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 3 more.
Overview
RNA reader protein, which recognises and binds specific RNAs, thereby regulating RNA metabolic processes, such as pre-mRNA splicing, circular RNA (circRNA) formation, mRNA export, mRNA stability and/or translation. Involved in various cellular processes, such as mRNA storage into stress granules, apoptosis, lipid deposition, interferon response, glial cell fate and development. Binds to the 5'-NACUAAY-N(1,20)-UAAY-3' RNA core sequence.
Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes affected pathway 0.76, literature 0.97, genetic association 0.00, somatic mutation 0.82, animal model 0.47). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Glioblastoma Multiforme, Melanoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · QKI (KH domain-containing RNA-binding protein QKI) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 3 more.
- 1 · What it is
QKI (KH domain-containing RNA-binding protein QKI) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 3 more.
- 2 · What goes wrong in cancer
RNA reader protein, which recognises and binds specific RNAs, thereby regulating RNA metabolic processes, such as pre-mRNA splicing, circular RNA (circRNA) formation, mRNA export, mRNA stability and/or translation.
- 3 · How drugs use it
No product in this corpus aims at QKI yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:21100 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96PU8 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000112531 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.51, gastric cancer 0.50, melanoma 0.57, skin cancer 0.54, breast cancer 0.56 (GraphQL API, CC0)); IntOGen QKI (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
RNA reader protein, which recognises and binds specific RNAs, thereby regulating RNA metabolic processes, such as pre-mRNA splicing, circular RNA (circRNA) formation, mRNA export, mRNA stability and/or translation. Involved in various cellular processes, such as mRNA storage into stress granules, apoptosis, lipid deposition, interferon response, glial cell fate and development. Binds to the 5'-NACUAAY-N(1,20)-UAAY-3' RNA core sequence. Acts as a mRNA modification reader that specifically recognises and binds mRNA transcripts modified by internal N(7)-methylguanine (m7G). Promotes the formation of circular RNAs (circRNAs) during the epithelial to mesenchymal transition and in cardiomyocytes: acts by binding to sites flanking circRNA-forming exons. CircRNAs are produced by back-splicing circularisation of pre-mRNAs. Location: Nucleus; Cytoplasm; Cytoplasm, cytosol; Cytoplasm, Stress granule (UniProt). Locus 6q26 (HGNC).
- Breast cancer: Open Targets association 0.56 with breast cancer (MONDO_0007254)
- Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.51 with colorectal cancer (MONDO_0005575)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.50 with gastric cancer (MONDO_0001056)
- Melanoma: Open Targets association 0.57 with melanoma (MONDO_0005105); IntOGen driver in 1 cohort (MEL)
- Glioma & glioblastoma: IntOGen driver in 1 cohort (GBM)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"QKI" OR ABSTRACT:"QKI" OR TITLE:"QKI, KH domain containing RNA binding" OR ABSTRACT:"QKI, KH domain containing RNA binding" OR TITLE:"KH domain-containing RNA-binding protein QKI" OR ABSTRACT:"KH domain-containing RNA-binding protein QKI" OR TITLE:"QK3" OR ABSTRACT:"QK3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about QKI, not a curated reading list.